Stolz, DaianaPollak, VincentChhajed, Prashant N.Gysin, ChristianPflimlin, EricTamm, Michael2022-08-232022-08-232007-03-162009-03-16Chest. 2007 Mar;131(3):765-72. <a href="http://dx.doi.org/10.1378/chest.06-2308">Link to article on publisher's site</a>0012-3692 (Print)10.1378/chest.06-230817356091https://hdl.handle.net/20.500.14038/38382BACKGROUND: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing bronchoscopy. METHODS: One hundred twenty patients undergoing bronchoscopy were included. Patients with COPD were randomized to receive either 200 mug of salbutamol (n = 40) or placebo (n = 40) before bronchoscopy. Control patients (n = 40) did not receive any inhaled medication. Spirometry was performed before and 2 h after bronchoscopy in all patients. Sedative drug requirements and hemodynamic parameters were recorded. RESULTS: Hemodynamic findings before, during, and after bronchoscopy were similar in patients with COPD randomized to either salbutamol or placebo (p = not significant for all). Compared to prebronchoscopy values, postbronchoscopy percentage of predicted FEV(1) decreased significantly in all three groups: salbutamol (median, - 4.7%; interquartile range [IQR], - 13.3 to 6.6); placebo (median, - 4.8%; IQR, - 19.9 to 8.4); and control subjects (median, - 10.0%; IQR, - 20.2 to - 3.3) [p = 0.023]. The decrease in FEV(1) was similar in all three patient groups (p = 0.432). The relative change in FEV(1) was inversely correlated to the increasing severity of COPD as expressed by Global Initiative for Chronic Obstructive Lung Disease stages (p = 0.01). CONCLUSIONS: Premedication with an inhaled short-acting beta-agonist cannot be recommended in patients with COPD undergoing bronchoscopy.en-USAdministration, InhalationAdultAgedAged, 80 and overAlbuterolBronchodilator Agents*BronchoscopyDouble-Blind MethodFemaleForced Expiratory VolumeHumansMaleMiddle AgedPremedicationPulmonary Disease, Chronic ObstructiveStatistics as TopicVital CapacityLife SciencesMedicine and Health SciencesJournal Articlehttps://escholarship.umassmed.edu/oapubs/1248782915oapubs/1248